User Tools

Site Tools

Trace: • heart_failure
cardio:diuretics:chlorthalidone

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Next revision		Previous revision
cardio:diuretics:chlorthalidone [2026/02/15 03:23] – created andrew2393cnscardio:diuretics:chlorthalidone [2026/03/15 17:05] (current) – Create Chlorthalidone page wilkie
Line 1: Line 1:
-====== Chlorthalidone (Thalitone®) ====== +====== Chlorthalidone (Hygroton®) ======<WRAP right 340px><WRAP infobox>| | {{ :cardio:diuretics:chlorthalidone_structure.svg |}} |^ Chlorthalidone || Brand Names | Hygroton® || Drug Class | [[cardio:diuretics:thiazide:start|Thiazide-Like Diuretic]] || Primary Indications | [[cardio:hypertension:start|Hypertension]]; Edema || Blood Pressure Effect | ↓ BP (chronic) || Mortality Benefit | No (BP control) || Elimination | Renal || Black Box Warning | No || FDA Approval | 1960 |</WRAP></WRAP>===== Overview =====Chlorthalidone is a thiazide-like diuretic that inhibits the Na-Cl cotransporter in the distal convoluted tubule. It has a longer half-life and stronger BP reduction than HCTZ.<WRAP clear></WRAP>----===== Mechanism of Action =====**Primary Molecular Target**  * Na-Cl cotransporter (NCC) in distal convoluted tubule**Segment Effects**  * ↓ NaCl reabsorption in DCT  * ↑ Ca2+ reabsorption  * Mild natriuresis**Net Physiologic Outcomes**  * ↓ blood pressure (long-term)  * Mild diuresis  * ↓ urinary calcium----===== Indications =====  * First-line hypertension (preferred thiazide-like)  * Mild edema----<WRAP blackbox>===== Black Box Warning =====No black box warning.</WRAP>----<WRAP contra>===== Contraindications =====Absolute:  * AnuriaRelative / Caution:  * Gout  * Hyponatremia  * Hypokalemia  * Sulfonamide allergy (severe)</WRAP>----<WRAP details>===== Dosing =====Hypertension:  * 12.5–25 mg daily (typical)  * Max: 50 mg dailyEdema:  * 25–100 mg daily or divided</WRAP>----<WRAP details>===== Pharmacokinetics =====Absorption:  * OralBioavailability:  * ~65%Metabolism:  * MinimalHalf-life:  * ~40–60 hoursElimination:  * Renal</WRAP>----<WRAP details>===== Adverse Effects =====Common:  * Hypokalemia  * Hyponatremia  * Hyperuricemia  * HyperglycemiaSerious:  * Severe hyponatremia  * Arrhythmias from hypokalemia</WRAP>----<WRAP details>===== Drug Interactions =====Increased risk:  * Lithium (↑ levels)  * NSAIDs (↓ effect)Avoid combination:  * Other QT-prolonging meds if severe hypokalemia</WRAP>----<WRAP monitoring>===== Monitoring =====Labs:  * Electrolytes (Na+, K+)  * Uric acid  * GlucoseVitals:  * Blood pressureClinical:  * Gout symptoms  * Orthostasis</WRAP>----<WRAP pearls>===== Clinical Pearls =====  * Longer half-life than HCTZ  * Preferred in guidelines for BP control  * Increases calcium reabsorption</WRAP>----===== Comparison Within Class =====Compared to other [[cardio:diuretics:thiazide:start|thiazide diuretics]]:  * Longer duration than HCTZ  * More potent BP lowering  * Higher hypokalemia risk----===== Related =====  * [[cardio:diuretics:thiazide:start|Thiazide Diuretics]]  * [[cardio:hypertension:start|Hypertension]]  * [[cardio:diuretics:start|Diuretics]]
- +
-<WRAP right 340px> +
-<WRAP infobox> +
-^ Chlorthalidone | {{ :cardio:diuretics:chlortalidone.svg?150 |}} | +
-| Brand Name | Thalitone® | +
-| Drug Class | [[cardio:diuretics:start|Thiazide-like Diuretic]] | +
-| Primary Indication | Hypertension | +
-| Site of Action | Distal Convoluted Tubule | +
-| Mechanism | Na⁺/Cl⁻ Cotransporter Inhibition | +
-| Potassium Effect | ↓ (Hypokalemia risk) | +
-| Calcium Effect | ↑ Reabsorption | +
-| Half-Life | ~40–60 hours | +
-| Landmark Trial | ALLHAT | +
-| FDA Approval | 1960 | +
-</WRAP> +
-</WRAP> +
- +
-===== Overview ===== +
- +
-Chlorthalidone is a thiazide-like diuretic used primarily for the treatment of hypertension. +
- +
-Although often grouped with thiazides, chlorthalidone has a significantly longer half-life and stronger outcome data compared to [[cardio:diuretics:hydrochlorothiazide|Hydrochlorothiazide]]. +
- +
-It is frequently preferred in hypertension guidelines due to its durable 24-hour blood pressure control and cardiovascular outcome benefit. +
- +
-<WRAP clear></WRAP> +
- +
----- +
- +
-===== Mechanism of Action ===== +
- +
-**Site of Action** +
-  * Distal convoluted tubule   +
- +
-**Transporter Blocked** +
-  * Na⁺/Cl⁻ cotransporter (NCC)   +
- +
-**Physiologic Effects** +
-  * ↑ Sodium and water excretion   +
-  * ↑ Potassium excretion   +
-  * ↑ Calcium reabsorption   +
-  * ↓ Plasma volume   +
-  * ↓ Peripheral vascular resistance (long-term effect)   +
- +
-Net effect: +
-  * Sustained blood pressure reduction   +
- +
----- +
- +
-===== Indications ===== +
- +
-  * Primary hypertension   +
-  * Edema (less commonly)   +
- +
-Supported by: +
-  * ALLHAT trial — reduction in cardiovascular events   +
- +
-Often combined with: +
-  * [[cardio:raas:ace|ACE inhibitors]]   +
-  * [[cardio:raas:arbs|ARBs]]   +
-  * [[cardio:beta_blockers:start|Beta-blockers]]   +
- +
----- +
- +
-<WRAP contra> +
-===== Contraindications ===== +
- +
-Absolute: +
-  * Anuria   +
- +
-Relative / Caution: +
-  * Severe renal impairment (reduced efficacy when eGFR < 30)   +
-  * Gout   +
-  * Hyponatremia   +
-  * Hypokalemia   +
-  * Diabetes mellitus   +
- +
-</WRAP> +
- +
----- +
- +
-<WRAP details> +
-===== Dosing ===== +
- +
-Hypertension: +
-  * 12.5–25 mg once daily   +
- +
-Higher doses: +
-  * Increase metabolic side effects   +
-  * Provide minimal additional BP reduction   +
- +
-Long half-life supports once-daily dosing with sustained effect. +
- +
-</WRAP> +
- +
----- +
- +
-<WRAP details> +
-===== Pharmacokinetics ===== +
- +
-Absorption: +
-  * Oral   +
- +
-Half-life: +
-  * ~40–60 hours   +
- +
-Duration: +
-  * >24-hour BP control   +
- +
-Elimination: +
-  * Renal   +
- +
-Longer duration compared to hydrochlorothiazide. +
- +
-</WRAP> +
- +
----- +
- +
-<WRAP details> +
-===== Adverse Effects ===== +
- +
-Electrolyte: +
-  * Hypokalemia   +
-  * Hyponatremia   +
-  * Hypomagnesemia   +
-  * Hypercalcemia   +
- +
-Metabolic: +
-  * Hyperglycemia   +
-  * Hyperuricemia (gout)   +
-  * Mild dyslipidemia   +
- +
-Other: +
-  * Photosensitivity   +
- +
-Electrolyte abnormalities may be more pronounced than with HCTZ. +
- +
-</WRAP> +
- +
----- +
- +
-<WRAP details> +
-===== Drug Interactions ===== +
- +
-Lithium: +
-  * Increased lithium levels   +
- +
-RAAS inhibitors: +
-  * May blunt potassium loss   +
- +
-Loop diuretics: +
-  * Additive electrolyte depletion   +
- +
-</WRAP> +
- +
----- +
- +
-<WRAP monitoring> +
-===== Monitoring ===== +
- +
-  * Blood pressure   +
-  * Electrolytes (Na⁺, K⁺)   +
-  * Renal function   +
-  * Uric acid (if gout risk)   +
-  * Glucose (diabetics)   +
- +
-</WRAP> +
- +
----- +
- +
-<WRAP pearls> +
-===== Clinical Pearls ===== +
- +
-  * Longer half-life than hydrochlorothiazide.   +
-  * Strong cardiovascular outcome data (ALLHAT).   +
-  * Often preferred thiazide for hypertension.   +
-  * More sustained 24-hour BP control.   +
-  * Greater risk of electrolyte abnormalities than HCTZ.   +
- +
-</WRAP> +
- +
----- +
- +
-===== Comparison Within Class ===== +
- +
-Compared to [[cardio:diuretics:hydrochlorothiazide|Hydrochlorothiazide]]: +
-  * Longer half-life   +
-  * Better cardiovascular outcome data   +
-  * More potent   +
- +
-Compared to [[cardio:diuretics:indapamide|Indapamide]]: +
-  * Similar mechanism   +
-  * Slightly different metabolic profile   +
- +
-Compared to [[cardio:diuretics:furosemide|Furosemide]]: +
-  * Less potent diuretic   +
-  * Not effective in severe renal failure   +
- +
----- +
- +
-===== Related ===== +
- +
-  * [[cardio:diuretics:start|Diuretics]] +
-  * [[cardio:diuretics:hydrochlorothiazide|Hydrochlorothiazide]] +
-  * [[cardio:hypertension:start|Hypertension]] +
-  * [[cardio:raas:ace_inhibitors:start|ACE Inhibitors]]====== Chlorthalidone (Thalitone®) ====== +
- +
-<WRAP right 340px> +
-<WRAP infobox> +
-| | {{ :cardio:diuretics:chlorthalidone.svg?180 |}} | +
-^ Chlorthalidone | +
-| Brand Name | Thalitone® | +
-| Drug Class | [[cardio:diuretics:start|Thiazide-like Diuretic]] | +
-| Primary Indication | Hypertension | +
-| Site of Action | Distal Convoluted Tubule | +
-| Mechanism | Na⁺/Cl⁻ Cotransporter Inhibition | +
-| Potassium Effect | ↓ (Hypokalemia risk) | +
-| Calcium Effect | ↑ Reabsorption | +
-| Half-Life | ~40–60 hours | +
-| Landmark Trial | ALLHAT | +
-| FDA Approval | 1960 | +
-</WRAP> +
-</WRAP> +
- +
-===== Overview ===== +
- +
-Chlorthalidone is a thiazide-like diuretic used primarily for the treatment of hypertension. +
- +
-Although often grouped with thiazides, chlorthalidone has a significantly longer half-life and stronger outcome data compared to [[cardio:diuretics:hydrochlorothiazide|Hydrochlorothiazide]]. +
- +
-It is frequently preferred in hypertension guidelines due to its durable 24-hour blood pressure control and cardiovascular outcome benefit. +
- +
-<WRAP clear></WRAP> +
- +
----- +
- +
-===== Mechanism of Action ===== +
- +
-**Site of Action** +
-  * Distal convoluted tubule   +
- +
-**Transporter Blocked** +
-  * Na⁺/Cl⁻ cotransporter (NCC)   +
- +
-**Physiologic Effects** +
-  * ↑ Sodium and water excretion   +
-  * ↑ Potassium excretion   +
-  * ↑ Calcium reabsorption   +
-  * ↓ Plasma volume   +
-  * ↓ Peripheral vascular resistance (long-term effect)   +
- +
-Net effect: +
-  * Sustained blood pressure reduction   +
- +
----- +
- +
-===== Indications ===== +
- +
-  * Primary hypertension   +
-  * Edema (less commonly)   +
- +
-Supported by: +
-  * ALLHAT trial — reduction in cardiovascular events   +
- +
-Often combined with: +
-  * [[cardio:raas:ace_inhibitors:start|ACE inhibitors]]   +
-  * [[cardio:raas:arbs:start|ARBs]]   +
-  * [[cardio:beta_blockers:start|Beta-blockers]]   +
- +
----- +
- +
-<WRAP contra> +
-===== Contraindications ===== +
- +
-Absolute: +
-  * Anuria   +
- +
-Relative / Caution: +
-  * Severe renal impairment (reduced efficacy when eGFR < 30)   +
-  * Gout   +
-  * Hyponatremia   +
-  * Hypokalemia   +
-  * Diabetes mellitus   +
- +
-</WRAP> +
- +
----- +
- +
-<WRAP details> +
-===== Dosing ===== +
- +
-Hypertension: +
-  * 12.5–25 mg once daily   +
- +
-Higher doses: +
-  * Increase metabolic side effects   +
-  * Provide minimal additional BP reduction   +
- +
-Long half-life supports once-daily dosing with sustained effect. +
- +
-</WRAP> +
- +
----- +
- +
-<WRAP details> +
-===== Pharmacokinetics ===== +
- +
-Absorption: +
-  * Oral   +
- +
-Half-life: +
-  * ~40–60 hours   +
- +
-Duration: +
-  * >24-hour BP control   +
- +
-Elimination: +
-  * Renal   +
- +
-Longer duration compared to hydrochlorothiazide. +
- +
-</WRAP> +
- +
----- +
- +
-<WRAP details> +
-===== Adverse Effects ===== +
- +
-Electrolyte: +
-  * Hypokalemia   +
-  * Hyponatremia   +
-  * Hypomagnesemia   +
-  * Hypercalcemia   +
- +
-Metabolic: +
-  * Hyperglycemia   +
-  * Hyperuricemia (gout)   +
-  * Mild dyslipidemia   +
- +
-Other: +
-  * Photosensitivity   +
- +
-Electrolyte abnormalities may be more pronounced than with HCTZ. +
- +
-</WRAP> +
- +
----- +
- +
-<WRAP details> +
-===== Drug Interactions ===== +
- +
-Lithium: +
-  * Increased lithium levels   +
- +
-RAAS inhibitors: +
-  * May blunt potassium loss   +
- +
-Loop diuretics: +
-  * Additive electrolyte depletion   +
- +
-</WRAP> +
- +
----- +
- +
-<WRAP monitoring> +
-===== Monitoring ===== +
- +
-  * Blood pressure   +
-  * Electrolytes (Na⁺, K⁺)   +
-  * Renal function   +
-  * Uric acid (if gout risk)   +
-  * Glucose (diabetics)   +
- +
-</WRAP> +
- +
----- +
- +
-<WRAP pearls> +
-===== Clinical Pearls ===== +
- +
-  * Longer half-life than hydrochlorothiazide.   +
-  * Strong cardiovascular outcome data (ALLHAT).   +
-  * Often preferred thiazide for hypertension.   +
-  * More sustained 24-hour BP control.   +
-  * Greater risk of electrolyte abnormalities than HCTZ.   +
- +
-</WRAP> +
- +
----- +
- +
-===== Comparison Within Class ===== +
- +
-Compared to [[cardio:diuretics:hydrochlorothiazide|Hydrochlorothiazide]]: +
-  * Longer half-life   +
-  * Better cardiovascular outcome data   +
-  * More potent   +
- +
-Compared to [[cardio:diuretics:indapamide|Indapamide]]: +
-  * Similar mechanism   +
-  * Slightly different metabolic profile   +
- +
-Compared to [[cardio:diuretics:furosemide|Furosemide]]: +
-  * Less potent diuretic   +
-  * Not effective in severe renal failure   +
- +
----- +
- +
-===== Related ===== +
- +
-  * [[cardio:diuretics:start|Diuretics]] +
-  * [[cardio:diuretics:hydrochlorothiazide|Hydrochlorothiazide]] +
-  * [[cardio:hypertension:start|Hypertension]] +
-  * [[cardio:raas:ace_inhibitors:start|ACE Inhibitors]]+
cardio/diuretics/chlorthalidone.1771125795.txt.gz · Last modified: by andrew2393cns